Vansen Pharma Inc.
company.status.inactiveCIK 1378076fmd_13W0ZW58DCE72G0MPKRS86RPG2Mining · Gold and Silver OresTemplate: Standard
Coverage: Jan 01, 2006 to Sep 30, 2013, 18 periods
Latest annual · FY2012
Millions- Net income
- (0)
Latest quarter · Q3 FY2013
Millions- Total revenues
- 1
- Gross profit
- 0
- Operating income
- (2)
- Net income
- (0)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2007 to FY2012
- n/m
Vansen Pharma Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2012 | FY2011 | Change | Source |
|---|---|---|---|---|
| Net income | -$37,148 | -$25,064 | 10-K 2013-04-12 · proof | |
| Cash from operating activities | -$28,751 | -$20,422 | 10-K 2013-04-12 · proof | |
| Total assets | $15,015 | $18,766 | -20% | 10-K 2013-04-12 · proof |
| Total liabilities | $119,478 | $117,546 | +1.6% | 10-K 2013-04-12 · proof |
| Cash and cash equivalents | $15,015 | $18,766 | -20% | 10-K 2013-04-12 · proof |
- What was Vansen Pharma Inc.'s net income in fiscal 2012?
- Vansen Pharma Inc. reported net income of -$37,148 for fiscal 2012 (the year ended Dec 31, 2012), against -$25,064 the year before. Source: the 10-K filed with the SEC on Apr 12, 2013. SEC
- What was Vansen Pharma Inc.'s cash from operating activities in fiscal 2012?
- Vansen Pharma Inc. reported cash from operating activities of -$28,751 for fiscal 2012 (the year ended Dec 31, 2012), against -$20,422 the year before. Source: the 10-K filed with the SEC on Apr 12, 2013. SEC
- What are Vansen Pharma Inc.'s total assets?
- As of Dec 31, 2012, Vansen Pharma Inc. reported total assets of $15,015, against $18,766 a year earlier (-20%). Source: the 10-K filed with the SEC on Apr 12, 2013. SEC
- What are Vansen Pharma Inc.'s total liabilities?
- As of Dec 31, 2012, Vansen Pharma Inc. reported total liabilities of $119,478, against $117,546 a year earlier (+1.6%). Source: the 10-K filed with the SEC on Apr 12, 2013. SEC
- What are Vansen Pharma Inc.'s cash and cash equivalents?
- As of Dec 31, 2012, Vansen Pharma Inc. reported cash and cash equivalents of $15,015, against $18,766 a year earlier (-20%). Source: the 10-K filed with the SEC on Apr 12, 2013. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1378076&period_type=annual&limit=5"Information only, not investment advice.